Activest Wealth Management Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Activest Wealth Management reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 61.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,324 shares of the company’s stock after selling 2,100 shares during the quarter. Activest Wealth Management’s holdings in Moderna were worth $88,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Moderna by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,132,777 shares of the company’s stock valued at $142,533,000 after buying an additional 83,082 shares in the last quarter. Banco Santander S.A. purchased a new position in shares of Moderna in the third quarter valued at about $3,550,000. John G Ullman & Associates Inc. grew its position in shares of Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after buying an additional 38,400 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Moderna by 51.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 85,473 shares of the company’s stock valued at $5,712,000 after purchasing an additional 29,177 shares during the period. Finally, Cornerstone Advisors LLC lifted its position in shares of Moderna by 80.0% in the 3rd quarter. Cornerstone Advisors LLC now owns 1,800 shares of the company’s stock worth $120,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent research reports. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. Berenberg Bank began coverage on shares of Moderna in a research note on Tuesday. They issued a “hold” rating and a $42.00 price target for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Wolfe Research assumed coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $84.00.

Moderna Trading Down 0.6 %

Shares of MRNA traded down $0.24 during trading hours on Thursday, reaching $36.70. 925,775 shares of the company traded hands, compared to its average volume of 4,765,115. The stock’s fifty day moving average price is $56.13 and its 200 day moving average price is $95.05. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $14.12 billion, a price-to-earnings ratio of -6.35 and a beta of 1.69. Moderna, Inc. has a 12-month low of $35.80 and a 12-month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the firm earned ($1.39) EPS. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -9.44 earnings per share for the current year.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 2,930 shares of company stock worth $217,170 in the last ninety days. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.